1. Pharmacogenomics of celiprolol – evidence for a role of P‐glycoprotein and organic anion transporting polypeptide 1A2 in celiprolol pharmacokinetics
- Author
-
Mikko Niemi, Maria Paile-Hyvärinen, Mikko Neuvonen, Janne T. Backman, Tuija Tapaninen, Aleksi Tornio, and Päivi Hirvensalo
- Subjects
Candidate gene ,ATP Binding Cassette Transporter, Subfamily B ,Genotype ,Organic Anion Transporters ,RM1-950 ,Pharmacology ,Polymorphism, Single Nucleotide ,030226 pharmacology & pharmacy ,General Biochemistry, Genetics and Molecular Biology ,03 medical and health sciences ,0302 clinical medicine ,Pharmacokinetics ,medicine ,Humans ,ATP Binding Cassette Transporter, Subfamily B, Member 1 ,General Pharmacology, Toxicology and Pharmaceutics ,Celiprolol ,030304 developmental biology ,P-glycoprotein ,0303 health sciences ,biology ,Chemistry ,General Neuroscience ,Haplotype ,General Medicine ,Organic anion-transporting polypeptide ,Pharmacogenetics ,biology.protein ,Therapeutics. Pharmacology ,Public aspects of medicine ,RA1-1270 ,Candidate Gene Analysis ,medicine.drug - Abstract
The aim of this study was to search for associations of genetic variants with celiprolol pharmacokinetics in a large set of pharmacokinetic genes, and, more specifically, in a set of previously identified candidate genes ABCB1, SLCO1A2, and SLCO2B1. To this end, we determined celiprolol single‐dose (200 mg) pharmacokinetics and sequenced 379 pharmacokinetic genes in 195 healthy volunteers. Analysis with 46,064 common sequence variants in the 379 genes did not identify any novel genes associated with celiprolol exposure. The candidate gene analysis showed that the ABCB1 c.3435T>C and c.2677T/G>A, and the SLCO1A2 c.516A>C variants were associated with reduced celiprolol area under the plasma concentration‐time curve (AUC0–∞). An alternative analysis with ABCB1 haplotypes showed that, in addition to SLCO1A2 c.516A>C, three ABCB1 haplotypes were associated with reduced celiprolol AUC0–∞. A genotype scoring system was developed based on these variants and applied to stratify the participants to low and high celiprolol exposure genotype groups. The mean AUC0–∞ of celiprolol in the low exposure genotype group was 55% of the mean AUC0–∞ in the high exposure group (p = 1.08 × 10−11). In addition, the results showed gene‐gene interactions in the effects of SLCO1A2 and ABCB1 variants on celiprolol AUC0–∞ (p
- Published
- 2021